Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D.
Business Of Biotech
00:00
The Reverse Merger of Metzemic and Bone Therapeutics
We decided to put 51% of Metzemic into bone therapeutics, which gave us anyways the major part of the shares at that point coming out of this transaction. And we decided that the 49% were going to stay on the side for two years or two or three years. We went to the fact that they were valued at 10 millions and we were valued at 80 million. It's a little bit easier than for us private company where everything was not public and where to develop and show what we were doing.
Transcript
Play full episode
